Researchers seek to short-circuit Alzheimer’s. Drug intended to stop disease before it starts to be tested

The Boston Globe reports on a new drug being tested concerning Alzheimer's:

Initial findings showed that an experimental drug from Cambridge biotech company Biogen reduced the levels of abnormal proteins in the brain called amyloid plaques, believed to be markers for the disease. The improvement was seen in a small group of patients who already have mild memory and thinking impairments, and that reduction correlated with a slowing of their mental decline.

Progress.